Isatuximab 联合 RRMM 中的新型药物 - 主方案
1-2 期 UMBRELLA 试验评估 Isatuximab 联合或不联合地塞米松联合新型药物与 Isatuximab 联合泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤 (RRMM) - 主方案
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.
研究概览
地位
条件
详细说明
Participants will continue study treatment until disease progression, death, unacceptable toxicity, participant request to stop treatment, Investigator decision, or study termination by the Sponsor i.e., up to Aapproximately 28 months.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Trial Transparency email recommended (Toll free number for US & Canada)
- 电话号码:option 6 800-633-1610
- 邮箱:contact-us@sanofi.com
学习地点
-
-
-
Jerusalem、以色列、9112001
- 招聘中
- Investigational Site Number : 3760002
-
Ramat Gan、以色列、5262100
- 招聘中
- Investigational Site Number : 3760003
-
Tel Aviv、以色列、6423906
- 招聘中
- Investigational Site Number : 3760001
-
-
-
-
-
Athens、希腊、115 28
- 招聘中
- Investigational Site Number : 3000001
-
Athens、希腊、106 76
- 招聘中
- Investigational Site Number : 3000002
-
-
-
-
-
Frankfurt、德国、60590
- 招聘中
- Investigational Site Number : 2760006
-
Lübeck、德国、23562
- 招聘中
- Investigational Site Number : 2760008
-
-
-
-
Reggio Emilia
-
Meldola、Reggio Emilia、意大利、47014
- 招聘中
- Investigational Site Number : 3800001
-
-
-
-
-
Oslo、挪威、0450
- 招聘中
- Investigational Site Number : 5780001
-
-
-
-
-
Lille、法国、59037
- 招聘中
- Investigational Site Number : 2500002
-
Nantes、法国、44093
- 招聘中
- Investigational Site Number : 2500001
-
Paris、法国、75013
- 招聘中
- Investigational Site Number : 2500003
-
Paris、法国、75015
- 招聘中
- Investigational Site Number : 2500004
-
-
-
-
Puerto Rico
-
Hato Rey、Puerto Rico、波多黎各、00917
- 完全的
- Puerto Rico Medical Research Center- Site Number : 8400005
-
-
-
-
New South Wales
-
Wollongong、New South Wales、澳大利亚、2500
- 招聘中
- Investigational Site Number : 0360006
-
-
Victoria
-
Heidelberg、Victoria、澳大利亚、3084
- 完全的
- Investigational Site Number : 0360003
-
Melbourne、Victoria、澳大利亚、3065
- 招聘中
- Investigational Site Number : 0360002
-
Richmond、Victoria、澳大利亚、3121
- 招聘中
- Investigational Site Number : 0360001
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- 完全的
- University of Alabama at Birmingham- Site Number : 8400001
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 招聘中
- Winship Cancer Institute of Emory University- Site Number : 8400010
-
-
Illinois
-
Chicago、Illinois、美国、60612
- 完全的
- University of Illinois-Chicago - College of Medicine- Site Number : 8400007
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- University of Michigan Health System - Ann Arbor- Site Number : 8400004
-
-
New York
-
Buffalo、New York、美国、14263
- 招聘中
- Roswell Park Cancer Institute- Site Number : 8400008
-
-
Ohio
-
Columbus、Ohio、美国、43210
- 招聘中
- The Ohio State University- Site Number : 8400012
-
-
-
-
Seoul-teukbyeolsi
-
Seoul、Seoul-teukbyeolsi、韩国、03722
- 招聘中
- Investigational Site Number : 4100004
-
Seoul、Seoul-teukbyeolsi、韩国、06351
- 招聘中
- Investigational Site Number : 4100002
-
Seoul、Seoul-teukbyeolsi、韩国、03080
- 招聘中
- Investigational Site Number : 4100001
-
Seoul、Seoul-teukbyeolsi、韩国、06591
- 招聘中
- Investigational Site Number : 4100003
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Participant must be 18 years of age inclusive or older.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
-
Participants with relapsed or refractory MM who have received at least 2 prior lines of therapy for MM, including PIs and IMiDs (eg, Induction regimen with autologous stem cell transplant followed by maintenance is considered one line).
-
RRMM with measurable disease:
- Serum M protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
- Urine M protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
- Serum free light chain (sFLC) MM without measurable M protein in serum or urine per previous criteria (serum Ig free light chain ≥10 mg/dL and abnormal serum Ig kappa lambda free light chain ratio <0.26 or >1.65).
-
Men or woman or childbearing potential should agree to use contraception.
-
Substudy 01, 06: Anti-CD38 therapy naïve or prior exposure to such drugs with a wash out of at least 12 months after the last dose. "Exposure" is defined as at least 2 cycles of therapy.
-
Substudies 02, 03: Anti-CD38 therapy naïve or prior exposure to such drugs without being refractory but with a wash out of at least 6 months after the last dose. "Refractory" is defined as progressing within 60 days of last dose of anti-CD38 targeting therapy.
-
Substudy 04: Anti-CD38 and anti-B cell maturation antigen (BCMA) therapy (if available) prior exposed participants with RRMM. For anti-CD38, "Exposure" is defined as at least 2 cycles of therapy. For anti-BCMA therapy if available, exposure is defined by at least 2 cycles of therapy.
-
Substudy 05: Participants with RRMM with at least 2 cycles of prior exposure to anti-CD38 therapy. For participants to whom BCMA targeted therapy is available (ie, approved in their region and can be reimbursed), at least 2 cycles of prior exposure to a BCMA targeted agent is mandatory.
Exclusion Criteria:
- Primary systemic amyloid light chain amyloidosis, plasma cell leukemia, monoclonal gammopathy of undetermined significance, or smoldering myeloma.
- Uncontrolled infection within 14 days prior to first study intervention administration.
- Clinically significant cardiac (including valvular) or vascular disease within 3 months prior to first study intervention administration., eg, myocardial infarction, unstable angina, coronary (eg, coronary artery bypass graft, percutaneous coronary intervention) or peripheral artery revascularization, left ventricular ejection fraction <40%, heart failure New York Heart Association Classes III and IV, stroke, transient ischemic attack, pulmonary embolism, other thromboembolic event, or cardiac arrhythmia (Grade 3 or higher by NCI CTCAE Version 5.0).
- Known acquired immunodeficiency syndrome-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A.
- Uncontrolled or active hepatitis B virus (HBV) infection.
- Active hepatitis C virus (HCV) infection.
- Any of the following within 3 months prior to first study intervention administration: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease.
- Second malignancy other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma, unless they are successfully treated with curative intent for more than 3 years before first study intervention administration.
- Any anti-MM drug treatment within 14 days before first study intervention administration, including dexamethasone.
- Participants with a contraindication to treatment.
- Vaccination with a live vaccine 4 weeks before the start of the study.
- Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.
- Hemoglobin <8 g/dL.
- Platelets <50 × 10^9/L.
- Absolute neutrophil count <1.0 × 10^9/L.
- Creatinine clearance <30 mL/min/1.73m2.
- Total bilirubin >1.5 × ULN, except for known Gilbert syndrome in which direct bilirubin should be ≤2.5 × ULN.
- Aspartate aminotransferase and/or alanine aminotransferase >3 × ULN.
- Patients with grade 3 or 4 hypercalcemia.
Substudy 01:
-Malabsorption syndrome or any condition that can significantly impact the absorption of pomalidomide.
Substudy 02:
- History of resected/ablated basal or squamous cell carcinoma (SCC) of the skin or carcinoma in situ of the cervix, or other local tumors, even if considered cured by local treatment.
- Therapeutic doses of anticoagulants or antiplatelet agents within 7 days prior to the first dose of SAR439459.
- Prothrombin time or INR >1.5 × upper limit of normal (ULN).
Substudy 03:
- Current corneal epithelial disease except mild punctate keratopathy.
- Patients who have received prior therapy with belantamab mafodotin.
Substudy 04:
- Central nervous system or leptomeningeal disease.
- Medical history of seizure.
- Participants currently receiving hepatically metabolized narrow therapeutic index drugs (eg, digoxin, warfarin) if cannot be closely monitored.
- Active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs), except controlled by replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc). The following are not exclusionary: vitiligo, childhood asthma that has resolved, psoriasis that does not require systemic treatment.
- Prior allogeneic hematopoietic stem cell transplant (allo-HSCT).
Substudy 05:
- Participant unable to swallow tablets.
Substudy 06:
- History of active autoimmune disorders.
- History of autoimmune hemolytic anemia or autoimmune. thrombocytopenia.
- Active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD.
- Prior allogenic hematopoietic stem cell transplant (allo-HSCT).
- Patient with chronic active EBV infection.
- Patients with known history of HLH.
- Hemoglobin < 9 g/dL.
- Prior therapy with any anti-CD47 or anti signal regulatory protein alpha agent.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 01)
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
其他名称:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: Capsule; Route of administration: Oral
其他名称:
|
|
实验性的:isatuximab + SAR439459 + dexamethasone (Substudy 02)
SAR439459 in combination with isatuximab and dexamethasone Part 1: 2 dose levels (DLs) of IV SAR439459:
Part 2:
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
其他名称:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: Solution for injection; Route of administration: Intravenous |
|
实验性的:isatuximab + dexamethasone + belantamab mafodotin (Substudy 03)
Belantamab mafodotin in combination with isatuximab and dexamethasone Part 1: 1 DL of IV belantamab mafodotin in Part 1 and de-escalation dose DL-1:
Part 2:
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
其他名称:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
其他名称:
|
|
实验性的:Isatuximab + pegenzileukin (Substudy 04)
Pegenzileukin in combination with isatuximab Part 1- dose escalation:
Part 1 - dose optimization:
Part 2 (dose expansion):
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
其他名称:
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
其他名称:
|
|
实验性的:Experimental: Isatuximab + Dexamethasone + Belumosudil (Substudy 05)
Isatuximab in combination with belumosudil and dexamethasone Part 1- dose escalation: During the first cycle, belumosudil will be evaluated in monotherapy during 2 to 4 weeks, then isatuximab and dexamethasone will be added, and continued for the subsequent cycles.
Part 1- dose optimization:
Part 2- dose expansion:
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
其他名称:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: tablet; route of administration: oral
其他名称:
|
|
实验性的:Isatuximab + evorpacept + dexamethasone (Substudy 06)
Isatuximab in combination with evorpacept and dexamethasone Part 1- dose escalation:
Part 2- dose expansion:
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
其他名称:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab
大体时间:Through the end of cycle 1 (approximately 6 weeks)
|
Determination or confirmation of the dose will be based on: safety and tolerability in terms of TEAEs/SAEs, dose-limiting toxicity occurrence, and laboratory parameters available information on PK (if appropriate) and biomarkers. |
Through the end of cycle 1 (approximately 6 weeks)
|
|
Part 2 (expansion, controlled experimental substudies): VGPR Rate (Rate of Very Good Partial Response Rate or Better)
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Part 2 (expansion, independent experimental substudies): Overall Response Rate (ORR) in independent experimental substudies
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
新型药物(实验臂)和ISATUXIMAB(COTROUGH)的浓度
大体时间:周期1期间的多个时间点。周期为28天。
|
周期1期间的多个时间点。周期为28天。
|
|
|
第一次输注(CMAX)对belumosudil-替代观察到的最大浓度-05
大体时间:周期1期间的多个时间点。周期为28天。
|
周期1期间的多个时间点。周期为28天。
|
|
|
是时候到达belumosudil的CMAX(TMAX)-BESTUDY 05
大体时间:周期1期间的多个时间点。周期为28天。
|
周期1期间的多个时间点。周期为28天。
|
|
|
浓度与时间曲线的面积使用梯形方法从0到8H(AUC0-8H)计算为Belumosudil -bessudy 05
大体时间:周期1期间的多个时间点。周期为28天。
|
周期1期间的多个时间点。周期为28天。
|
|
|
第一次输注后观察到的最大浓度(CMAX) - evorpacept -bessudy 06
大体时间:周期1期间的多个时间点。周期为28天。
|
周期1期间的多个时间点。周期为28天。
|
|
|
是时候到达evorpacept的CMAX(TMAX)-BESTUDY 06
大体时间:周期1期间的多个时间点。周期为28天。
|
周期1期间的多个时间点。周期为28天。
|
|
|
浓度与时间曲线的面积使用梯形方法计算的evorpacept(AUC0-T)的梯形方法计算的面积
大体时间:周期1期间的多个时间点。周期为28天。
|
周期1期间的多个时间点。周期为28天。
|
|
|
Part 1 (dose finding, experimental substudies): ORR
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Part 2 (expansion, controlled experimental substudies): ORR
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Part 1 (dose finding, experimental substudies): VGPR or better
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Part 2 (expansion, independent experimental substudies): VGPR or better
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Clinical benefit rate (CBR) in each treatment arm
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
CBR, defined as the proportion of participants with sCR, CR, VGPR, PR, or minimal response, according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Duration of Response (DOR) in each treatment arm
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
DOR, defined as the time from the date of the first response that is subsequently confirmed for patients achieving PR or better to the date of first documented PD or death, whichever happens first. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Time to First Response (TT1R) in each treatment arm
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
TT1R, defined as the time from the date of first treatment to the date of first response (PR or better) that is subsequently confirmed. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Time to Best Response (TTBR) in each treatment arm
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
TTBR, defined as the time from the date of first treatment to the date of first occurrence of best overall response (PR or better) that is subsequently confirmed. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Number of participants with treatment emergent adverse events and serious adverse events in each treatment arm
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
Safety and tolerability assessed in terms of adverse events/SAEs, including second primary malignancies, laboratory parameters, vital signs, and findings from physical examination. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Progression-free survival (PFS) in each treatment arm
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
PFS is defined as the time from the date of first treatment to disease progression based on the Investigator assessment according to 2016 IMWG criteria or death from any cause, whichever happens first. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Overall Survival (OS) in each treatment arm
大体时间:Up to approximately 28 months after the First patient in or scheduled assessment
|
OS is defined as the time from the date of first treatment to death from any cause. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Immunogenicity of isatuximab and novel agents
大体时间:Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment
|
Incidence of anti-drug antibodies (ADAs) for novel agents (experimental arms) and isatuximab. |
Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment
|
|
Disease-specific HRQL will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30)
大体时间:On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
The EORTC QLQ-C30 will be used to assess cancer-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies). |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
Disease- and treatment-related quality of life will be assessed using the EORTC multiple myeloma module (QLQ-MY20) questionnaire
大体时间:On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
The EORTC QLQ-MY20 will be used to measure myeloma-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies). |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
Global impact of side effects will be assessed using the Functional Assessment of Cancer Therapy (FACT-G) (GP5)
大体时间:On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
A single item from the FACT-G GP5 will be used to assess the global impact of side effects. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies). |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
Estimate/Confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores using the Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales
大体时间:On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales will be utilized as anchors to estimate/confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies). |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
The intensity of skeletal-related events (SRE)- related bone pain will be assessed using the skeletal-related bone pain numeric rating scale (SRE-BP-NRS) for control and experimental arms -Substudy 02
大体时间:On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
The SRE-BP-NRS) will be used to assess the intensity of SRE-related bone pain (on average and at its worst) for control arm only |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
SRE Incidence for control and experimental arms- Substudy 02
大体时间:Continuous throughout study assessment (up to approximately 28 months)
|
SRE incidence, defined as the proportion of participants who experienced pathological fracture, radiation to bone, spinal cord compression, or surgery to bone as a first bone event. |
Continuous throughout study assessment (up to approximately 28 months)
|
|
Time to First Occurrence of SRE Assessment for control and experimental arms (Substudy 02)
大体时间:Continuous throughout study assessment (up to approximately 28 months)
|
Time to first occurrence of SRE is defined as time from the date of randomization to the occurrence of first SRE. |
Continuous throughout study assessment (up to approximately 28 months)
|
|
Assessment of Health care resource utilization related with SREs for control and experimental arms -Substudy 02
大体时间:On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.
|
The Health Care Resource Use-SREs questionnaire (HCRU-SREs) will be used to assess the use of health care resources associated with these events. |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.
|
|
To assess patient-reported visual functioning for experimental arm only -Substudy 03
大体时间:On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.
|
An NEI VFQ-25 will be used to assess patient-reported visual functioning. |
On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.
|
合作者和调查者
赞助
调查人员
- 研究主任:Clinical Sciences & Operations、Sanofi
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- ACT16482
- 2020-003024-16 (EudraCT编号)
- U1111-1244-2598 (注册表标识符:ICTRP)
- 2024-514988-25 (注册表标识符:CTIS)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.